09:19 AM EDT, 04/23/2024 (MT Newswires) -- BeiGene ( BGNE ) said Tuesday that tislelizumab has received approval from the European Commission to treat non-small cell lung cancer in three indications, including first- and second-line use.

The approval was based on the company's three late-stage trials in the Rationale program that had 1,499 participants. All three trials met their primary endpoints of improved survival rates, the oncology company said.

Tislelizumab is a humanized immunoglobulin G4 anti-programmed cell death protein 1 monoclonal antibody, BeiGene ( BGNE ) said.

Shares of the company were up 3.3% in recent Tuesday premarket activity.